190 related articles for article (PubMed ID: 18687447)
21. Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.
Ottone T; Hasan SK; Montefusco E; Curzi P; Mays AN; Chessa L; Ferrari A; Conte E; Noguera NI; Lavorgna S; Ammatuna E; Divona M; Bovetti K; Amadori S; Grimwade D; Lo-Coco F
Genes Chromosomes Cancer; 2009 Mar; 48(3):213-21. PubMed ID: 19023877
[TBL] [Abstract][Full Text] [Related]
22. Acute myeloid leukaemia induced by mitoxantrone: case report.
Arruda WO; Montú MB; de Oliveira Mde S; Ramina R
Arq Neuropsiquiatr; 2005 Jun; 63(2A):327-9. PubMed ID: 16100984
[TBL] [Abstract][Full Text] [Related]
23. Mitoxantrone (Novantrone) in multiple sclerosis: new insights.
Neuhaus O; Kieseier BC; Hartung HP
Expert Rev Neurother; 2004 Jan; 4(1):17-26. PubMed ID: 15853611
[TBL] [Abstract][Full Text] [Related]
24. Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
Taube F; Stölzel F; Thiede C; Ehninger G; Laniado M; Schaich M
Haematologica; 2011 Jun; 96(6):e31. PubMed ID: 21632839
[No Abstract] [Full Text] [Related]
25. The first case of mitoxantrone exposure in early pregnancy.
De Santis M; Straface G; Cavaliere AF; Rosati P; Batocchi AP; Caruso A
Neurotoxicology; 2007 May; 28(3):696-7. PubMed ID: 17227680
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Marburg variant multiple sclerosis with mitoxantrone.
Jeffery DR; Lefkowitz DS; Crittenden JP
J Neuroimaging; 2004 Jan; 14(1):58-62. PubMed ID: 14748210
[TBL] [Abstract][Full Text] [Related]
27. Mitoxantrone for multiple sclerosis causing acute lymphoblastic leukemia.
Cartwright MS; Jeffery DR; Lewis ZT; Koty PP; Stewart WT; Molnár I
Neurology; 2007 May; 68(19):1630-1. PubMed ID: 17485652
[No Abstract] [Full Text] [Related]
28. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
Singhal BS; Geeta S; Hundalani SG; Menon S
Neurol India; 2009; 57(4):418-23. PubMed ID: 19770542
[TBL] [Abstract][Full Text] [Related]
29. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
Pula JH; Javed A
Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
[TBL] [Abstract][Full Text] [Related]
30. [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].
Ory S; Debouverie M; Le Page E; Pelletier J; Malikova I; Gout O; Roullet E; Vermersch P; Edan G
Rev Neurol (Paris); 2008 Dec; 164(12):1028-34. PubMed ID: 18808781
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of mitoxantrone in multiple sclerosis--what is known?
Neuhaus O; Kieseier BC; Hartung HP
J Neurol Sci; 2004 Aug; 223(1):25-7. PubMed ID: 15261556
[TBL] [Abstract][Full Text] [Related]
32. [Therapy of multiple sclerosis].
Simó M
Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
[TBL] [Abstract][Full Text] [Related]
33. Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
Ellis R; Brown S; Boggild M
Mult Scler; 2015 Apr; 21(5):642-5. PubMed ID: 25013152
[TBL] [Abstract][Full Text] [Related]
34. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
Killestein J; van der Meer ML; Regelink JC; Huijgens PC; Polman CH
Neurology; 2010 Mar; 74(11):934; author reply 934. PubMed ID: 20231672
[No Abstract] [Full Text] [Related]
35. [Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone].
Nollet S; Berger E; Deconinck E; Baldauf E; Rumbach L
Rev Neurol (Paris); 2006 Feb; 162(2):195-9. PubMed ID: 16518259
[TBL] [Abstract][Full Text] [Related]
36. Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
Betancourt-García RD; Castro J; Fernández AC; López-Enríquez A; Fradera J; Pacheco E
P R Health Sci J; 2009 Jun; 28(2):146-50. PubMed ID: 19530558
[TBL] [Abstract][Full Text] [Related]
37. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.
Martinelli V; Cocco E; Capra R; Salemi G; Gallo P; Capobianco M; Pesci I; Ghezzi A; Pozzilli C; Lugaresi A; Bellantonio P; Amato MP; Grimaldi LM; Trojano M; Mancardi GL; Bergamaschi R; Gasperini C; Rodegher M; Straffi L; Ponzio M; Comi G;
Neurology; 2011 Nov; 77(21):1887-95. PubMed ID: 22076543
[TBL] [Abstract][Full Text] [Related]
38. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.
Brassat D; Recher C; Waubant E; Le Page E; Rigal-Huguet F; Laurent G; Edan G; Clanet M
Neurology; 2002 Sep; 59(6):954-5. PubMed ID: 12297591
[TBL] [Abstract][Full Text] [Related]
39. Dose-dependent melanonychia by mitoxantrone.
Reinsberger C; Meuth SG; Wiendl H
Mult Scler; 2009 Sep; 15(9):1131-2. PubMed ID: 19570819
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy and multiple sclerosis: The devil is in the details.
Bourdette D; Whitham R
Neurology; 2010 May; 74(18):1410-1. PubMed ID: 20439842
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
